Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Precancerous Conditions 1Keratosis, Actinic 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Excipients × Dermatologic × Clear all
NCT02844777 2023-01-12

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

Vidac Pharma

Phase 2 Completed
93 enrolled 13 charts
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡